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ABSTRACT
Cyclin D1 gene (CCND1) is a critical mitogen-
regulated cell-cycle control element whose tran-
scriptional modulation plays a crucial role in breast
cancer growth and progression. Here we demon-
strate that the non-aromatizable androgen 5-a-
dihydrotestosterone (DHT) inhibits endogenous
cyclin D1 expression, as evidenced by reduction of
cyclin D1 mRNA and protein levels, and decrease of
CCND1-promoter activity, in MCF-7 cells. The
DHT-dependent inhibition of CCND1 gene activity
requires the involvement and the integrity of the
androgen receptor (AR) DNA-binding domain. Site
directed mutagenesis, DNA affinity precipitation
assay, electrophoretic mobility shift assay and chro-
matin immunoprecipitation analyses indicate that
this inhibitory effect is ligand dependent and it is
mediated by direct binding of AR to an androgen
response element (CCND1-ARE) located at  570 to
 556-bp upstream of the transcription start site, in
the cyclin D1 proximal promoter. Moreover, AR-
mediated repression of the CCND1 involves the re-
cruitment of the atypical orphan nuclear receptor
DAX1 as a component of a multiprotein repressor
complex also embracing the participation of
Histone Deacetylase 1. In conclusion, identification
of the CCND1-ARE allows defining cyclin D1 as a
specific androgen target gene in breast and might
contribute to explain the molecular basis of the in-
hibitory role of androgens on breast cancer cells
proliferation.
INTRODUCTION
Over-expression of cyclin D1 has been linked to breast
cancer growth and progression (1–4), as well as develop-
ment of resistance to hormone therapy (5–8). The bio-
logically relevant role of cyclin D1 in breast
tumourigenesis has been evidenced by several ﬁndings:
mammary gland-targeted cyclin D1 over-expression
resulted in mammary hyperplasia and adenocarcinoma
in transgenic mice (9); cyclin D1 antisense blocked
ErbB2-induced mammary tumour growth in vivo (10),
and cyclin D1-deﬁcient mice were resistant to ErbB2- or
Ras-induced mammary tumourigenesis (11). In addition,
the correlation between cyclin D1 expression levels and
cellular proliferation in breast cancer cells has been
further conﬁrmed by silencing experiments (1,12).
Several hormones are involved in breast cancer cells
proliferation, so that cyclin D1 represents an important
target of their intracellular-signalling pathways (13–17).
Emerging evidences indicate that the androgen-
signalling pathway mainly exerts inhibitory eﬀects on the
growth of normal mammary epithelial cells and plays a
protective role in the pathogenesis of breast cancer
(18–21). Nonetheless, there are also some epidemiologic
reports supporting the concept that androgens, in certain
settings, can contribute to breast cancer growth (22–23).
Androgens excess (e.g. in congenital adrenal hyperplasia)
suppresses breast development (20), while mice lacking a
functional androgen receptor (AR) display defective
mammary gland development and morphogenesis (21).
Furthermore, in vivo studies evidenced that blocking the
action of endogenous androgens results in a signiﬁcant
increase in mammary epithelial cell proliferation (24–25).
In vitro, androgen signalling may counteract the prolif-
erative eﬀect of estrogens in AR-positive breast cancer
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markedly decreases oestrogen receptor a (ERa) transcrip-
tional activity (27–28). Furthermore, the non-
aromatizable androgen 5-a-dihydrotestosterone (DHT) is
able to inhibit serum as well as estradiol-induced prolifer-
ation in ERa positive breast cancer cell lines (18,28–31),
through a mechanism involving an increase in AR protein
cell content (28) concomitantly with the down-regulation
of the G1/S transition of the cell cycle (28,30).
The AR is present in both primary breast tumours
(70–90%) and metastases (75%) (32–34) and shows sig-
niﬁcant association with important clinical and pathologic
prognostic factors (35), since AR expression and function-
al activity correlate with a low tumour grade, smaller
tumour size, improved response to hormone therapy and
longer patient survival (33,35–41). Conversely, reduced or
impaired AR signalling has been demonstrated in heredi-
tary male breast cancer (42) as well as in HER2-positive
breast cancers, generally associated with a worse outcome
(43). Androgens have been previously used in the adjuvant
therapy of breast cancer in both pre-menopausal and
post-menopausal women, with an eﬃcacy comparable
to that of current hormonal treatment (44–45), and
combined hormonal therapy using tamoxifen plus the
androgen ﬂuoxymesterone oﬀered some therapeutic ad-
vantage over tamoxifen alone in metastatic breast carcin-
oma (45). Furthermore, it has been suggested that in
AR-positive breast cancer cells and breast carcinomas,
the anti-proliferative eﬀect of aromatase inhibitors seems
to be due not only to the reduction in estrogens biosyn-
thesis but also to the unmasking of the inhibitory eﬀect of
androgens acting via the AR (46–47).
Thus, AR is not only frequently expressed in breast
tumours and related to prognosis (48), but it also may
serve as a predictive marker for adjuvant hormonal
therapy (49). However, events following AR activation
and leading to inhibition of cell growth are not clearly
identiﬁed in breast cancer cells.
Here we investigated whether DHT-dependent inhib-
ition of breast cancer cell proliferation might be due to
the modulation of cyclin D1, whose induction represents
a key rate-limiting event in mitogenic signalling leading to
S-phase entry. We report the identiﬁcation of a novel
androgen-mediated mechanism that controls the expres-
sionofcyclinD1inMCF-7breastcancercellsbynegatively
regulating cyclin D1 transcript and protein levels. Indeed,
weidentiﬁed,inthehumancyclinD1promoterafunctional
androgen responsive element (ARE), which binds the AR
in response to DHT stimulation. Transcriptional repres-
sion of CCND1 by AR appears to be consequent to the
recruitment of a multiprotein repressor complex involving
the participation of the AR corepressor DAX1 and con-
taining histone deacetylase activity.
MATERIALS AND METHODS
Cell culture and treatments
Breast cancer epithelial cell line MCF-7 and human em-
bryonic kidney cell line HEK-293 were grown in
DMEM/F12 (Gibco, USA) supplemented with 5% calf
serum (CS; Gibco) and in DMEM plus 10% foetal calf
serum, respectively. 5a-DHT) (Sigma, USA) and
hydroxyﬂutamide (OH-Fl; Sigma) were used at a concen-
tration of 10
 7M and 10
 6M, respectively. Before each
experiment, cells were grown in phenol red-free (PRF)
DMEM, containing 5% charcoal-treated foetal calf
serum (PRF–CT) for 3days and then serum starved in
PRF for 24h to synchronize the cells. All the experiments
were performed in 2.5% PRF–CT.
Cell proliferation assays
MCF-7 cells were seeded on six-well plates (10
5 cells/well)
in 2.5% PRF–CT. After 24h, cells were exposed for 3days
to 10
 7M DHT and/or 10
 6M OHFl or left untreated.
Media were renewed daily. The eﬀects of the various drugs
on cell proliferation were measured 0, 24, 48 and 72h
following initial exposure to treatments by counting
MCF-7 cells using a Burker’s chamber, with cell viability
determined by trypan blue dye exclusion.
In the same experimental conditions, cell viability was
also examined using the method of transcriptional and
translational (MTT) colorimetric assay (50). At the
above indicated time points, 100ml of MTT (5mg/ml)
were added to each well, and the plates were incubated
for 4h at 37 C. Then, 1ml 0.04N HCl in isopropanol was
added to solubilise the cells. The absorbance was
measured with the Ultrospec 2100 Prospectrophotometer
(Amersham-Biosciences, Italy) at a test wavelength of
570nm.
Cell-cycle analysis
MCF-7 cells were seeded on six-well plates (10
5cells/well)
in 2.5% PRF–CT. After 24h, cells were exposed to
10
 7M DHT or left untreated. Cell-cycle analysis was
performed 72h following initial exposure to treatment as
previously described (28).
Plasmids, transfections and luciferase reporter assays
The following plasmids were used: pcDNA3-AR (AR)
encoding full-length AR [27]; CMV-P881
(AR(Cys574!Arg)) encoding the full-length AR carrying a
mutation in the DNA-binding domain (DBD;
Cys-574!Arg) (51); D1-2960, D1-944, D1-848,
D1-254, D1-136 and D1-96, carrying fragments
from the human CCND1 promoter and inserted into the
luciferase vector pXP2 (a gift from Dr A. Weitz,
University of Naples, Italy); the vector-based pSiAR
plasmid, coding for small interfering RNA targeting the
50-untranslated region of AR mRNA, and the scrambled
control construct pSiCon (52); The Renilla reniformis
luciferase expression vector used was pRL-Tk (Promega,
USA). MCF-7 cells were transfected using Fugene 6
(Roche, CH, USA) according to the manufacturer’s in-
structions. pRL-Tk was used to assess transfection eﬃ-
ciency. Luciferase activity was measured using dual
luciferase assay System (Promega), normalized to renilla
luciferase activity and expressed as relative luciferase
units.
For western blotting (WB) assays, MCF-7 cells were
plated on 60-mm dishes and transfected with an
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ﬁgure legends.
Immunoprecipitation and WB
Total cell proteins and the cytoplasmic and nuclear frac-
tions were obtained from 70% conﬂuent cell cultures.
Immunoprecipitation (IP) and WB were performed as pre-
viously described (53). The following monoclonal (m) and
polyclonal (p) antibodies (Ab) were used: anti-AR mAb
(441), anti-DAX1 pAb (K-17), anti-Lamin B pAb (C-20),
anti-GAPDH pAb (FL-335) and normal mouse immuno-
globulin G (Ig) (Santa Cruz Biotechnology, USA).
Real-time reverse transcription–PCR
Total RNA was isolated using TRIzol reagent (Invitrogen,
USA) according to the manufacturer’s instructions and
treated with DNase I (Ambion, Austin, TX, USA). Two
micrograms of total RNA were reverse transcribed with
the ImProm-II Reverse transcription system kit
(Promega); cDNA was diluted 1:3 in nuclease-free
water and 5ml were analysed in triplicates by real-time
PCR in an iCycler iQ Detection System (Bio-Rad, USA)
using SYBR Green Universal PCR Master Mix (Bio-Rad)
with 0.1mmol/l of each primer in a total volume of 30ml
reaction mixture. Primers used for the ampliﬁcation were
50-CGTGGCCTCTAAGATGAAGGA-30 (forward) and
50-CGGTGTAGATGCACAGCTTCTC-30 (reverse).
Negative controls contained water instead of ﬁrst strand
cDNA. Each sample was normalized on its 18S rRNA
content. The 18S quantiﬁcation was done using a
TaqMan rRNA Reagent kit (Applied Biosystems, USA)
following the manufacturer instructions. The relative
gene expression levels were normalized to a calibrator
that was chosen to be the basal, untreated sample.
Final results were expressed as n-fold diﬀerences in gene
expression relative to 18S rRNA and calibrator,
calculated using the Ct method as follows:
n-fold=2
 (Ctsample–Ctcalibrator), where Ct values of
the sample and calibrator were determined by subtracting
the average Ct value of the 18S rRNA reference gene
from the average Ct value of the diﬀerent genes analysed.
Site-directed mutagenesis
The cyclin D1 promoter plasmids bearing the AR respon-
sive (CCND1-ARE) mutated sites (D1-944mARE) were
created by site-directed mutagenesis using Quick Change
kit (Stratagene, La Jolla, CA, USA), as previously
described (54), using the following mutagenic primers
(mutations are shown as lowercase letters): CCND1-
ARE (forward) 50-TTGTGTGCCCGGTCCTCCCCGT
CCTTGCATaaaAAATTAGggtTTGCAATTTACACGT
GTTAATGAAA-30 and CCND1-ARE (reverse) 50-TTTC
ATTAACACGTGTAAATTGCA AaccCTAATTTtttAT
GCAAGGACGGGGAGGACCGGGCACACAA-30;
Sp1 (forward) 50-GCCCCCTCCCCCTGCaaCCaaCC
CCaaCaCCCTCCCGCTCCCAT-30 and Sp1 (reverse)
50-ATGGGAGCGGGAGGGtGttGGGGttGGttGCAG
GGGGAGGGGGC-30. The mutated expression vectors
were conﬁrmed by DNA sequencing.
DNA aﬃnity precipitation assay
DNA aﬃnity precipitation assay was performed as previ-
ously described (55). The DNA motif probes were
prepared by annealing a biotinylated sense oligonucleotide
(for CCND1-ARE, 50-[Bio]-GCTAAATTAGTTCTTGC
AATTTAC-30; for CCND1-mutatedARE, 50-[Bio]-CAT
AAAA-AATTAGGGTTTGCAAT-30; for Sp1, 50-[Bio]-
TGCCCGCGCCCCCTCCCCCTGCGCCCG-CCCCCG
CCCCCCT-30) with the respective unbiotinylated comple-
mentary oligonucleotide (for CCND1-ARE, 50-GTAAAT
TGCAAGAACTAATTTAGC-30; for CCND1-
mutatedARE, 50-ATTGCAAACCCTAATTTTTTATG
-30; for Sp1, 50-AGGGGGGCGGGGGCGGGCGCAG
GGG-GAGGGGGCGCGGGCA-30).
Electrophoretic mobility shift assay
Nuclear protein extracts were prepared as previously
described (54). The double-stranded oligonucleotides
used as probes were end labelled with
[g–32P]ATP and T4
polynucleotide kinase and puriﬁed using Sephadex G50
spin columns. The oligonucleotides used as probes and
as cold competitors (Sigma Genosys, UK) were: (nucleo-
tide motifs of interest are underlined): Probe: 50-TGCATG
CTAAAATAGTTCTTGCAA-30; Mutated probe;
50-TGCATaaaAAAATAGggtTTG-CAA-30. Nuclear
extracts (20mg) were incubated with 50000c.p.m. of
labelled probe, under conditions previously reported
(54). The mixture was incubated at room temperature
for 20min in the presence or absence of the unlabelled
competitor oligonucleotide. Mouse anti-AR monoclonal
antibody (441), or rabbit anti-AR polyclonal antibody
(C-19) or normal rabbit IgG (Santa Cruz
Biotechnology), were included in some of the reaction
mixtures with an additional 12-h incubation at 4 C
before addition of labelled probe. The entire reaction
mixture was electrophoresed through a 6% polyacryl-
amide gel for 3h at 150V.
Chromatin IP
Chromatin IP (ChIP) assay was performed as previously
described (56). The immuno-cleared chromatin was
precipitated with anti-AR mAb, anti-DAX1 pAb, anti-
Polymerase II pAb, anti-HDAC1 mAb, anti-HDAC3
pAb and anti-AIB1 mAb (Santa Cruz, USA). A 4-ml
volume of each sample was used as template for PCR
with speciﬁc primers. The following speciﬁc primer pairs
were used to amplify 168bp of the ARE-containing cyclin
D1 promoter fragment: 50-TACCCCTTGGGCATTTGC
AACGA-30 (forward); 50-ACAGACGGCCAAAGAATC
TCA-30 (reverse), and 228bp of the Sp1-sites containing
cyclin D1 promoter fragment 50-GGCGATTTGCATTTC
TATGA-30 (forward) and 50-CAAAACTCCCCTGTAGT
CCGT-30 (reverse).
Immunoprecipitated DNA was also analysed in tripli-
cates by real-time PCR by using 5ml of the diluted (1:3)
template DNA as described earlier. The following primer
pairs were used: 50-GCGCCGGAATGAAACTTG-30
(forward); 50-CTGCATCTTCTTTCATTTTCATTAAC
AC-30 (reverse) to amplify the ARE-containing cylin D1
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with respect to unprocessed lysates (input DNA). Inputs
DNA quantiﬁcation was performed by using 5ml of the
diluted (1/50) template DNA. The relative antibody-
bound fractions were normalized to a calibrator that
was chosen to be the basal, untreated sample. Final
results were expressed as fold diﬀerences with respect to
the relative inputs.
RNA silencing
For AR gene silencing experiments, MCF-7 cells were
transfected using the vector-based pSiAR plasmid or the
scrambled control construct pSiCon (52), as described in
the ‘Plasmids, transfections and luciferase reporter assays’
paragraph.
For DAX1 gene silencing experiments, custom
synthesized siRNA (Ambion) annealed duplexes were
used for eﬀective depletion of DAX1 mRNA. A
scrambled siRNA that does not match with any human
mRNA was used as a control for non-sequence-speciﬁc
eﬀects (Ambion). Growing cells were switched to PRF
for 24h and then switched to PRF–CT medium for 48h.
After that, cells were trypsinized and transfected in sus-
pension with 5nM siRNA (siDAX1 or scrambled siRNA)
in 35-mm dishes, using Lipofectamine 2000 (Invitrogen),
following the manufactuer0s instructions. Cells were
incubated with the siRNA-Lipofectamine 2000 complex
at 37 C for 4h and then switched to fresh PRF and
treated or not with DHT (10
 7M) for 72h before
analysis. For ChIP assay 100nM siDAX1 was used to
silence 60% conﬂuent cells plated in 150-mm dishes.
Statistical analysis
All data were expressed as the mean±SD of at least three
independent experiments. Statistical signiﬁcances were
tested using Student’s t-test.
RESULTS
DHT administration inhibits serum-induced MCF-7 cells
proliferation
We previously demonstrated that MCF-7 cells are
androgen responsive and that DHT treatment induces a
transient increase in AR protein levels (27), similar to
those seen in other cell types (57).
To investigate the role of activated AR on breast cancer
cell proliferation, the response of MCF-7 cells to the
non-aromatizable androgen DHT and/or the AR antag-
onist OHFl was measured after 24, 48 and 72h of treat-
ment in PRF DMEM implemented with 2.5% of steroid-
depleted serum (PRF–CT). DHT concentration was
chosen based on previous studies demonstrating dose-
dependent inhibitory eﬀects of DHT on MCF-7 cells pro-
liferation (28,30).
As expected, cells grown in presence of PRF–CT
proliferated; DHT treatment instead inhibited
serum-induced MCF-7 cells proliferation and, by the
end of the treatment, the mean number of DHT-treated
cells was  30% of respective controls. Addition of the AR
antagonist OHFl (or bicalutamide, data not shown) eﬀect-
ively reversed the inhibitory eﬀect of DHT on MCF-7 cells
proliferation, suggesting that it was mediated by the AR
(Figure 1A). A similar pattern of DHT-dependent eﬀect
on MCF-7 cells proliferation was obtained by
simultaneously performed MTT colorimetric assay
(Figure 1B). These data well correlated with cell-cycle
analysis showing an increase of the percentage of cells in
G0/G1 phase and a concurrent decrease in the S phase,
following 72h of DHT treatment. At this time point the
presence of sub-G1 apoptotic cells was undetectable
(Figure 1C).
Activated AR decreases cyclin D1 expression and
promoter activity’
Since DHT administration reduces the G1/S phase transi-
tion in MCF-7 cells (28,30), we inquired whether
DHT-induced decrease of MCF-7 cells proliferation
might be consequent to the modulation of cyclin D1 ex-
pression, whose induction represents a key rate-limiting
event in mitogenic signalling leading to S-phase entry.
To this aim, serum starved MCF-7 cells were left untreat-
ed or treated with 10
 7M DHT for 24h, 48h or 72h and
cyclin D1 expression was assessed by real-time RT–PCR
and WB analysis. As shown in Figure 2A, MCF-7 cells
exhibited a decrease in the serum-dependent levels of
cyclin D1 mRNA (Figure 2A) and protein (Figure 2B)
following 48 and 72h of DHT treatment. The involvement
of the AR in the negative regulation of cyclin D1 expres-
sion was ascertained by silencing AR expression in MCF-7
cells (Figure 2B).
To test whether activated AR might negatively
modulate cyclin D1 promoter activity, MCF-7 cells were
transiently transfected with a cyclin D1 promoter reporter
plasmid (D1-2996) and left untreated or treated with
10
 7M DHT.
The cyclin D1 promoter was induced by serum, while
DHT treatment inhibited basal cyclin D1 promoter
activity, decreasing the serum-induced signal by  50%.
OHFl addition reversed this eﬀect, suggesting that it was
due to AR activation (Figure 2C).
To substantiate the AR involvement in the modulation
of CCND1 expression, we evaluated the eﬀects of ectopic
AR expression on the transcriptional activity of the cyclin
D1 promoter. HEK-293 cells, which do not express AR,
were co-transfected with the D1-2996 plasmid and
increasing amounts of a full length AR-encoding
plasmid. In the absence of exogenous AR expression,
DHT treatment cannot inﬂuence cyclin D1 promoter
activity. On the contrary, in the presence of ectopic AR,
a dose-dependent decrease in the serum-induced cyclin D1
promoter activity was observed upon DHT administration
(Figure 2D).
To investigate whether the eﬀect of AR on cyclin D1
promoter activity is dependent on its transactivation
properties, luciferase assay was performed in
AR-negative HEK-293 cells transfected with an expres-
sion plasmid encoding an AR carrying a mutation
(ARCys574!Arg) in the DBD, which disrupts its ability to
bind target DNA sequences (27,51). In these
5354 Nucleic Acids Research, 2010,Vol.38, No. 16circumstances, no decrease in cyclin D1 promoter activity
could be detected (Figure 2D), suggesting the existence, in
the cyclin D1 promoter, of putative androgen responsive
region(s).
Characterization of functional androgen responsive
region(s) in the cyclin D1 promoter
To deﬁne the AR responsive region(s) of the cyclin D1
promoter, a series of 50-promoter-deleted mutants were
used and tested for both androgen sensitivity and
promoter activity, in MCF-7 cells. The constructs
D1-2960, D1-944 and D1-848, which include
2.960kb, 0.944kb and 0.848kb of the cyclin D1
promoter fragment, respectively, showed a decreased tran-
scriptional activity upon DHT stimulation with respect to
untreated controls. A weaker inhibition of the cyclin D1
promoter signal was evidenced using the D1-254 and
D1-136 constructs, while the D1-96 plasmid, failed
to respond to DHT (Figure 3).
Sequence analysis of the  848bp to  254bp cyclin D1
promoter DNA fragment revealed a likely ARE sequence
(TGCTAAattAGTTCT) located at the  570bp position
of the promoter. This putative ARE (CCND1-ARE) is
homologous to the AREs found in the promoters of the
sc (sc-ARE1.2) and slp (slp-HRE2) genes (58) (Figure 4A).
To assess the relative importance of this sequence we used
site-directed mutagenesis to alter it. Nucleotide substitu-
tions were introduced into the  570-bp to  556-bp
fragment of D1-944 and the mutant promoter
D1-944-mARE was assayed in parallel with the
unmutated D1-944 promoter. Disruption of the
putative ARE consensus site resulted in a signiﬁcant loss
of the inhibitory eﬀect of DHT on cyclin D1 promoter
activity (Figure 4B). These results address the CCND1-
ARE as a crucial sequence in mediating cyclin D1
promoter inhibition upon DHT exposure.
Nevertheless, mutations at the putative ARE did not
completely abolish cyclin D1 promoter responsiveness to
DHT, as indicated by the persistence of a weak
DHT-induced decrease in the luciferase activity of the
D1-136 construct, containing two Sp1 sites. To investi-
gate whether this additional cis-element might be involved
in the androgen response, as previously demonstrated for
other AR target genes (57,58), site-directed mutagenesis
was used to introduce nucleotide substitutions into the
 117-bp to  101-bp fragment of D1-944
(D1-944-mSp1) or D1-944-mARE (D1-944-mARE/
Sp1) and the mutant promoters were assayed in functional
analysis. As depicted in Figure 4B, DHT treatment is able
to induce only an about 30% inhibition of D1-944-mSp1
promoter activity, indicating that Sp1 sites are important
for an AR full inhibitory eﬀect on the cyclin D1 promoter.
Consistent with these observations, mutation of both
ARE and Sp1 motifs completely abolishes DHT respon-
siveness of the cyclin D1 promoter further suggesting that
its regulation occurs through a functional interaction of
the AR with the CCND1-ARE and Sp1 responsive
sequences.
AR interacts with the ARE containing region of the
cyclin D1 promoter
To support the functional importance of the identiﬁed
ARE sequence, a double-stranded oligonucleotide con-
taining the putative ARE sequence was used in a DNA
aﬃnity precipitation assay (DAPA) to determine whether
AR can bind to the CCND1-ARE consensus sequence.
Endogenous AR was found associated with the putative
consensus oligonucleotide following DHT administration
only, while AR binding was undetectable in nuclear cell
lysates from untreated cells (Figure 5A). Moreover, AR
Figure 1. Proliferative response of MCF-7 cells to DHT. Serum
starved MCF-7 cells were grown in PRF–CT in absence or presence
of 10
 7M DHT and/or 10
 6M OH-Fl. The eﬀects of the various drugs
on cell proliferation were measured 0, 24, 48 and 72h following initial
exposure to treatments by: (A) cell counting using a Burker’s Chamber,
with cell viability determined by trypan blue dye exclusion or (B) the
MTT assay as described in ‘Materials and Methods’ section. (B) Serum
starved MCF-7 cells were grown in PRF–CT in absence or presence of
10
 7M DHT for 72h and then subjected to cell-cycle analysis as
described in ‘Materials and Methods’ section. Data, representing a
mean±SD of three independent experiments, each in triplicate, were
statistically analysed by Student’s t-test, *P<0.05 versus untreated.
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cyclin D1 promoter oligo in which the putative ARE con-
sensus site was mutated.
To further determine the speciﬁcity of the putative ARE
site we performed electrophoretic mobility shift assay
(EMSA). As shown in Figure 5B, factors present in
MCF-7 cells nuclear extracts retarded the mobility of
the putative ARE domain in a speciﬁc manner, since the
formation of a protein–DNA complex was found (Figure
5B, lane 1). Of note, DHT treatment induced a strong
increase in the protein–DNA association (Figure 5B,
lane 2) whose appearance was competed eﬀectively by a
100-fold molar excess of unlabelled probe (Figure 5B, lane
3), demonstrating the speciﬁcity of the DNA-binding
complex. This inhibition was no longer observed using a
mutated putative ARE oligonucleotide as competitor
(Figure 5B, lane 4). Contemporary administration of the
anti-androgen bicalutamide caused a dramatic decrease in
the DNA-binding complex induced by DHT (Figure 5B,
lane 6) suggesting that the AR is involved in the binding to
the CCND1-ARE. Finally the speciﬁcity of these bands
was proved by the drastic attenuation of the complex in
the presence of a mouse anti-AR monoclonal antibody,
indicating that this antibody recognizes AR epitopes
that interact or interfere with AR association to ARE
(Figure 5B, lane 7). Moreover, the addition of a rabbit
anti-AR polyclonal antibody to the EMSA generated a
molecular weight super shift (Figure 5B, lane 8), further
indicating the involvement of the AR. Normal rabbit IgG
addition did not aﬀect protein–DNA complex formation
(Figure 5B, lane 9).
To better determine the physiological relevance of the
CCND1-ARE, we investigated whether AR interacts with
this region of the CCND1 as it exist in native chromatin,
performing ChIP in AR-positive MCF-7 andT47D breast
cancer cells, using anti-AR or anti-RNA Polymerase (Pol)
II antibodies. AR occupancy of the CCND1-ARE con-
taining region of cyclin D1 promoter was induced in a
ligand-dependent manner, since AR recruitment was
enhanced by DHT (Figure 5C). The inhibitory role of
Figure 2. CCND1 expression and promoter activity are inhibited by DHT-activated AR. (A) Serum-starved MCF-7 cells were treated or left
untreated with 10
 7M DHT for 24, 48 or 72h in PRF–CT and total RNA was extracted. The abundance of cyclin D1 mRNA was detected by
real-time reverse transcription-PCR, as described in ‘Materials and Methods’ section. (B) Total proteins were isolated from MCF-7 cells transfected
with 0.5mg pSiAR or 0.5mg pSiCon scrambled control and treated for 24, 48 and 72h with 10
 7M DHT or left untreated in PRF–CT. A 50mgo f
protein lysates were analysed by WB to evaluate the expression of cyclin D1 and AR. The expression of b-actin was assessed as control of protein
loading. Results are representative of three independent experiments. (C) Serum-starved MCF-7 cells were transiently transfected with D1-2960
reporter plasmid (0.25mg/well). Upon transfection, cells were treated with 10
 7M DHT and/or 10
 6M OH-Fl, or left untreated in PRF–CT for 24h.
Fireﬂy luciferase activity was detected and expressed as percentage of Relative Luciferase Activity. Activation of the reporter gene D1-2960 in the
presence of PRF–CT is arbitrarily set at 100%. Results represent the means±SD of ﬁve separate experiments each in triplicate. Data were
statistically analysed by student’s t-test, *P<0.01 versus untreated. (D) AR negative HEK 293 cells were co-transfected with D1-2960
(0.25mg/well) plus increasing quantities (mg) of pcDNA3-AR (AR) or CMVP881 (ARCys-574!Arg) (0.5mg/well) as indicated. Upon transfection,
cells were treated with 10
 7M DHT, or left untreated in PRF–CT for 24h. Fireﬂy luciferase activity was detected and expressed as percentage
of relative luciferase activity. Activation of the reporter gene D1-2960 in the presence of PRF–CT is arbitrarily set at 100%. Linear relation
between transfected AR plasmid and expressed AR protein quantity was evaluated by WB. Results represent the mean±SD from ﬁve independent
experiments. Data were statistically analysed by Student’s t-test, *P<0.05 and  P<0.01 versus untreated.
5356 Nucleic Acids Research, 2010,Vol.38, No. 16AR on cyclin D1 promoter, is further evidenced by the
dynamic of RNA Pol II recruitment onto the cyclin D1
promoter, that appears to be drastically reduced upon
DHT treatment (Figure 5C).
AR associates with the SP1 sites present in the
cyclin D1 proximal promoter
To further investigate the functional importance of the
Sp1 sites in the AR-mediated modulation of the cyclin
D1 promoter, the ability of AR to associate to the Sp1
sites containing sequence of the cyclin D1 promoter (59)
was ﬁrst examined by DAPA. The association between
AR and the cyclin D1-Sp1 sequence was observed only
upon DHT treatment, while AR binding could not be
detected in nuclear cell lysates from untreated cells
(Figure 6A).
AR recruitment on the Sp1-containing region of the
endogenous cyclin D1 promoter was also investigated by
ChIP experiments using anti-AR or anti-RNA Pol II
antibodies. AR was recruited to the Sp1 sites containing
promoter region in a ligand-dependent manner.
Conversely, upon DHT administration, RNA Pol II was
released from the investigated promoter region
(Figure 6B) supporting the hypothesis that this
Sp1-containing DNA region might cooperate with the
CCND1-ARE site in the AR-dependent regulation of
CCND1.
The AR corepressor DAX1 is recruited at the CCND1-
ARE containing sequence of the cyclin D1 promoter
To assess whether the decrease of cyclin D1 promoter
transcriptional activity might be caused by the cooperative
interaction between AR and negative transcriptional
regulators, we investigated the involvement of the
orphan nuclear receptor DAX1, which has been shown
to interact with and function as a negative coregulator
of AR (60–62).
DAX1 abundance was analysed in cytoplasmic and
nuclear protein fractions obtained from MCF-7 cells
stimulated or not with 10
 7M DHT. DAX1 was mainly
present in the nuclear compartment and its abundance
increased upon DHT treatment (Figure 7A). To investi-
gate whether the DHT-induced enhancement of DAX1
expression is paralleled by an AR/DAX1 physical inter-
action, co-IP assay was performed on nuclear and cyto-
plasmic protein fractions from MCF-7 cells. The
formation of a AR/DAX1 complex was clearly evidenced
into the nucleus upon DHT administration (Figure 7B),
arguing for a DAX1 regulatory function on AR transcrip-
tional activity.
To test whether DAX1 could assemble on the androgen
responsive region of the cyclin D1 promoter, DAPA assay
was performed. The binding aﬃnity of DAX1 to the DNA
probe containing the putative CCND1-ARE site
(Figure 8A) or the Sp1 site (Figure 8B) was signiﬁcantly
changed in response to DHT. Furthermore, no binding of
another AR corepressor, such as SMRT, to the CCND1-
ARE containing DNA probe could be detected (data not
shown).
To verify that DAX1 is recruited within the androgen
responsive region of human cyclin D1 promoter in vivo,
ChIP assay was performed using anti-DAX1 antibody.
DAX1 occupancy of the CCND1-ARE containing
region of the cyclin D1 promoter signiﬁcantly increased
following DHT treatment. No recruitment of the steroid
receptor coactivator AIB1, was detected under the same
Figure 3. Functional analysis of the promoter regions involved in AR-mediated modulation of the cyclin D1 promoter. (Left panel) Schematic
representation of human cyclinD1 promoter fragments used in this study. All of the promoter constructs contain the same 30-boundary (+142). The
50-boundaries of the promoter fragments varied from  2960 to  96. (Right panel) Transcriptional activity of cyclin D1 promoter constructs following
DHT stimulation is shown. Serum-starved MCF-7 cells were transiently transfected with the indicated mutated plasmid (0.25mg/well), as reported in
‘Materials and Methods’ section. Upon transfection, cells were treated with 10
 7M DHT or left untreated in PRF–CT for 24h. Fireﬂy luciferase
activity was detected and expressed as percentage of Relative Luciferase Activity. Activation of reporter plasmids in the presence of PRF–CT only is
arbitrarily set at 100. Results represent the means±SD of three separate experiments each in triplicate. Data were statistically analysed by Student’s
t-test, *P<0.05 and  P<0.01 versus untreated.
Nucleic Acids Research, 2010,Vol.38, No. 16 5357experimental condition (Figure 8C and D), showing the
selectivity of corepressor recruitment. A similar pattern of
DAX1 recruitment to the Sp1-containing region of the
cyclin D1 promoter was observed (Figure 8E). Since
histone deacetylation represents at least one of the mech-
anisms by which repressor proteins mediate transcription-
al repression (63–64), we investigated HDAC1 and/or
HDAC3 association on the AR responsive sequences
within the cyclin D1 promoter by DAPA and ChIP
assays. In both assays, DHT stimulation induces the
recruitment of HDAC1 but not HDAC3 to either
the CCND1-ARE consensus sequence (Figure 8A, C
and D), or the Sp1 site (Figure 8B and E).
To conﬁrm the role of DAX1 in the AR-dependent
modulation of the CCND1, RNA silencing was used to
knockdown the expression of endogenous DAX1 in
MCF-7 cells. A 50% decrease of DAX1 protein levels
was achieved using anti-DAX1 siRNA in MCF-7 cells
after 48h (Figure 9A). ChIP analysis was then performed
on MCF-7 cells transfected with DAX1 siRNA or
scrambled control siRNA. Upon DHT stimulation,
DAX1 knockdown caused the recovery of RNA Pol II
recruitment within the CCND1-ARE (Figure 9B and C)
and Sp1 (Figure 9D) containing region of the cyclin D1
promoter, whereas the scrambled siRNA showed no eﬀect
on RNA Pol II dismissal. AR recruitment on the respon-
sive regions of the cyclin D1 promoter was not aﬀected by
DAX1 silencing (Figure 9B, C and D). Moreover, DAX1
knockdown resulted in the loss of the DHT inhibitory
eﬀect on cyclin D1 levels (Figure 9A), strengthening the
role of DAX1 as a component of the repressor complex
participating in the AR-dependent inhibition of the
CCND1.
DISCUSSION
The AR represents a common characteristic in breast
tumors, since it is expressed in a signiﬁcant subset
(60–90%) of both ERa-positive and -negative breast
cancers (33–35). AR expression in breast cancer tissue
samples has been shown to be associated with a better
prognosis (35,38–41,65–66). Conversely, lack of AR ex-
pression correlates with transformation from in situ to
invasive basal subtype of high-grade ductal breast carcin-
oma (48) and with a poor prognosis in lymph
node-positive ER/PR/Her2-negative breast cancers (41);
even though a recent report suggests that the AR may
participate to the development of invasive ductal carcin-
oma by repressing E-cadherin expression (67).
Despite the growing body of evidence indicating a pro-
tective role of AR in breast tumourigenesis, the mechan-
isms underlying the inhibition of the in vivo and/or in vitro
Figure 4. Mutations of the putative ARE site or the Sp1 sites reduce
the ability of AR to down-regulate cyclin D1 transcriptional activity.
(A) Representation of the putative ARE site location within the cyclin
D1 promoter. A list of known high aﬃnity AR-speciﬁc ARE sequences
is listed in the lower panel. (B) Site-directed mutagenesis was performed
as described in ‘Materials and Methods’ section. MCF-7 cells were
co-transfected, as reported in ‘Materials and Methods’ section, by
using the mutated promoter constructs, schematically represented in
(C). Upon transfection, cells were treated with 10
 7M DHT or left
untreated in PRF–CT for 24h. Fireﬂy luciferase activity was detected
and expressed as percentage of Relative Luciferase Activity. Activation
of reporter gene in the presence of PRF–CT is arbitrarily set at 100.
Results represent the means±SD of three separate experiments each in
triplicate. Data were statistically analysed by Student’s t-test, *P<0.05
and  P<0.01 versus control (C);
«P<0.01 versus DHT treated
D1-944.
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deﬁned.
In this report we provide evidence that DHT-activated
AR is a transcriptional repressor of the CCND1 in MCF-7
breast cancer cells. Analysis of the molecular events
associated with this hormone-induced negative regulation
of cyclin D1 expression allows, for the ﬁrst time, the iden-
tiﬁcation of a speciﬁc ARE within the CCND1 proximal
promoter, and recognizes the recruitment of DAX1 and
HDAC1 as components for AR-mediated transcriptional
repression.
Earlier studies have shown that DHT inhibits MCF-7
cells proliferation by targeting the G1/S transition of
the cell cycle (28,30). Here, we demonstrated that, in
MCF-7 cells, cyclin D1 expression is negatively modulated
by DHT administration as evidenced by reduction of
Figure 5. DHT induces activation of AR-DNA-binding activity in MCF-7 cells and AR recruitment to the ARE containing region of the cyclin D1
promoter. (A) Nuclear extracts from MCF-7 cells treated with 10
 7M DHT or left untreated in PRF–CT for 2h, were incubated with either a
biotinylated oligonucleotide containing the CCND1-ARE site or a biotinylated oligonucleotide mutated in the CCND1-ARE (mARE) consensus site
and subjected to DNA aﬃnity precipitation assay as described in ‘Materials and Methods’ section. Speciﬁcally bound proteins were subjected to WB
analysis using an antibody speciﬁc to AR. The speciﬁcity of the binding was tested by loading the unbound fraction (Negative control). MCF-7 cell
nuclear extracts were used as positive control. (B) Nuclear extracts from MCF-7 cells left untreated (lane 1) or treated with 10
 7M DHT for 2h
(lanes 2–4 and 6–9) were incubated with a double-stranded CCND1-ARE-speciﬁc consensus sequence probe labelled with [ 
32P]ATP and subjected to
electrophoresis in a 6% polyacrylamide gel. Competition experiments were done by adding as competitor a 100-fold molar excess of unlabelled probe
(lane 3) or a 100-fold molar excess of unlabelled oligonucleotide containing a mutated CCND1-ARE (lane 4). The formation of the DNA–AR
complex was blocked by the addition of 10
 5M Bicalutamide (lanes 5 and 6). The speciﬁcity of the binding was tested by adding an anti-AR
antibodies to the reaction mixture (lane 7-8) or IgG (lane 9). Lane 10 contains probe alone. (C) Chromatin IPs were carried out on serum starved
MCF-7 and T47D cells as described in ‘Materials and Methods’ section. Cells were treated with 10
 7M DHT or left untreated in PRF–CT for 2h,
lysed and DNA-associated proteins were precipitated using either anti-AR Ab or anti-RNA Pol II Ab (2mg/sample each). In control samples (Ig),
normal mouse or rabbit IgG, respectively, was used instead of the primary Abs as control of Ab speciﬁcity. The 50-ﬂanking sequence of the CCND1
containing the ARE site was detected by PCR with speciﬁc primers listed in ‘Materials and Methods’ section. Inputs DNA were ampliﬁed as loading
controls. (D) Five-microlitres volume of each sample and input from ChIP were used for real-time PCR as described in the ‘Materials and Methods’
section. Data were statistically analysed by Student’s t-test, *P<0.05 versus untreated.
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promoter activity. The involvement of activated AR in
this process is substantiated by the observation that in
AR-negative HEK-293 cells, DHT administration is able
to interfere with cyclin D1 promoter activity only in the
presence of exogenous AR expression. Moreover, the
DHT inhibitory eﬀect strictly depends on the integrity of
the AR-DBD, suggesting the existence, in the cyclin D1
promoter, of a putative androgen responsive region which
mediates androgen response.
A number of studies examined the domains important
for the functions of the cyclin D1 promoter demonstrating
that it is a complex transcriptional unit composed of
several distinct elements (17,59,68–70). Nevertheless, to
date, no androgen response elements (AREs) have been
identiﬁed within the cyclin D1 promoter. The present
study provides evidence that AR-mediated inhibition of
the CCND1 is consequent to direct binding of the AR to
a speciﬁc androgen responsive site, located at position
 570bp as indicated by deletion and sequence analyses
of the cyclin D1 proximal promoter. The identiﬁed
CCND1-ARE motif 50-TGCTAAattAGTTCT-30 resem-
bles the so-called selective AREs that exhibit characteris-
tics of partial direct repeats, instead of the conventional
inverted repeats of the 50-TGTTCT-30 monomer-binding
element, and are recognized exclusively by the AR
(58,71,72).
This CCND1-ARE is functional, as demonstrated by
transactivation studies, and capable to interact with the
AR, in a ligand-dependent manner as evidenced by DAPA
or EMSA. The physiological relevance of CCND1-ARE
within the cyclin D1 promoter in vivo is pointed out by
ChIP analysis showing that AR occupancy of the ARE
containing promoter region is concomitant with a
decrease in RNA Pol II recruitment, consistent with the
reduced cyclin D1 transcriptional activity.
Our study also indicates that AR binding to the Sp1
sites within the proximal cyclin D1 promoter is required
for a full DHT-dependent inhibition of cyclin D1
promoter activity. This observation is consistent with
previous studies on the organization of transcription
factor-binding sites within the regulatory regions of a se-
lection of androgen-responsive genes, showing that a key
feature of these genes is the presence of one or more
AR-binding site (ARE, HRE) together with binding se-
quences for housekeeping (Sp1, NF-1), inducible (NF-kB,
AP1) and tissue speciﬁc transcription factors (73).
Therefore, androgen-regulated gene expression appears
to be dependent on the coordinated interactions of the
receptor protein and other transcription factors.
Intriguingly, our data indicate that on CCND1 the
promoter-bound DHT–AR complex functions as an
inverse agonist, causing active repression of basal gene
activity, eventually creating a repressive chromatin con-
formation associated with reduced RNA Polymerase II
recruitment, in MCF-7 breast cancer cells.
Figure 6. DHT induces recruitment of AR to the Sp1-site containing
region of the cyclin D1 promoter. (A) Nuclear extracts from MCF-7
cells treated with 10
 7M DHT or left untreated in PRF–CT for 2h,
were incubated with a biotinylated oligonucleotide containing the
CCND1-Sp1 site and subjected to DNA aﬃnity precipitation assay as
described in the ‘Materials and Methods’ section. Speciﬁcally bound
proteins were subjected to WB analysis using an antibody speciﬁc to
AR. The speciﬁcity of the binding was tested by loading the unbound
fraction (Negative control). MCF-7 cell nuclear extracts were used as
positive control. (B) Chromatin IPs were carried out on serum starved
MCF-7 cells as described in the ‘Materials and Methods’ section. Cells
were treated with 10
 7M DHT or left untreated in PRF–CT for 2h,
lysed and DNA-associated proteins were precipitated using either
anti-AR Ab or anti-RNA Pol II Ab (2mg/sample each). In control
samples (Ig), normal mouse or rabbit IgG was used, respectively,
instead of the primary Abs as control of Ab speciﬁcity. The
50-ﬂanking sequence of the CCND1 containing the Sp1 site was
detected by PCR with speciﬁc primers listed in the ‘Materials and
Methods’ section. Inputs DNA were ampliﬁed as loading controls.
Results are representative of three independent experiments.
Figure 7. DHT induces the formation of a AR/DAX1 complex into
the nucleus. (A) Serum starved MCF-7 cells were treated with 10
 7M
DHT or left untreated in PRF–CT for 24h. The expression of DAX1
and AR was determined by WB using 50mg of either cytoplasmic or
nuclear protein lysates. The expression of GAPDH and Lamin B was
assessed as control of protein loading and purity of lysate fractions.
(B) Five hundred micrograms of either nuclear or cytoplasmic lysates
from MCF-7 cells, treated with 10
 7M DHT or left untreated in PRF–
CT for 24h, were immunoprecipitated (IP) with anti-AR mAb and
subjected to WB to detect DAX1 and AR protein levels. Results,
obtained after repetitive stripping and reprobing of the same ﬁlters,
are representative of three independent experiments.
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CCND1 involves the recruitment of the atypical orphan
nuclear receptor DAX1 that is expressed in tissues directly
involved in steroid hormone production and reproductive
function (74–75). DAX1 inhibits ligand-dependent trans-
activation by agonist-bound nuclear receptors like AR,
ER and progesterone receptor (60–61,76). Moreover,
DAX1 has been proposed to be involved in the develop-
ment of cancers of a variety of tissues and has been found
to positively correlate with AR and ER expression in
breast cancer specimens (60–61,74,77). Our results
suggest that, in MCF-7 cells, upon DHT stimulation,
DAX1 is recruited on the androgen responsive region of
the cyclin D1 promoter concomitantly to AR. The repres-
sor complex formation also embraces the participation of
HDAC1, further contributing to explain the AR-mediated
inhibition of CCND1 transcription (Figure 10).
Given the importance of cyclin D1 in breast cancer cell
proliferation, androgen-mediated regulation of cyclin D1
levels appears to play a crucial role in cell-cycle control.
Figure 8. DHT induces the recruitment of DAX1 and histone deacetylase 1 to the CCND1-ARE and Sp1 sites containing regions of the cyclin D1
promoter. (A) and (B) Nuclear extracts from MCF-7 cells treated with 10
 7M DHT or left untreated in PRF–CT for 2h were incubated with either
a biotinylated oligonucleotide containing the CCND1-ARE site (A) or the Sp1 site (B) and subjected to DNA aﬃnity precipitation assay as described
in the ‘Materials and Methods’ section. Speciﬁcally bound proteins were subjected to WB analysis using antibodies speciﬁc to DAX1, HDAC1 or
HDAC3. The speciﬁcity of the binding was tested by loading the unbound fraction (Negative control). MCF-7 cell nuclear extracts were used as
positive control. (C) Chromatin IPs were carried out on serum starved MCF-7 cells as described in the ‘Materials and Methods’ section. Cells were
treated with 10
 7M DHT or left untreated in PRF–CT for 2h, lysed and DNA-associated proteins were precipitated using antibodies (Ab) speciﬁc to
AR, AIB1, HDAC1, HDAC3 (2mg/sample each). In control samples (Ig), normal mouse or rabbit IgG was used instead of the primary Abs as
control of Ab speciﬁcity. The 50-ﬂanking sequence of the CCND1 containing the CCND1-ARE site was detected by PCR using speciﬁc primers listed
in the ‘Materials and Methods section. Inputs DNA were ampliﬁed as loading controls. (D) Five-microlitres volume of each sample and input from
ChIP were used for real-time PCR as described in the ‘Materials and Methods’ section. Data were statistically analysed by Student’s t-test, *P<0.05
versus untreated. (E) ChIP assays were carried out as above described. The 50-ﬂanking sequence of the CCND1 containing the Sp1 sites was detected
by PCR using speciﬁc primers reported in the ‘Materials and Methods’ section. Input DNAs were ampliﬁed as loading controls. Results are
representative of three independent experiments.
Nucleic Acids Research, 2010,Vol.38, No. 16 5361Figure 10. Proposed model for AR-mediated repression of the CCND1. In the absence of DHT, CCND1 basal activity is regulated by several serum
factors acting through multiple regulatory region of the cyclin D1 promoter and enabling a permissive chromatin conformation and gene transcrip-
tion (13,15,17). Upon DHT treatment, AR is recruited on the ARE- and Sp1-containing region of the proximal cyclin D1 promoter, causing
displacement of RNA Polymerase II and recruitment of a corepressor complex containing DAX1 and HDAC1, with consequent repression of
cyclin D1 expression.
Figure 9. Eﬀect of DAX1 knockdown on the modulation of CCND1 expression by AR.(A) Total cellular proteins were isolated from MCF-7 cells
transfected with 5nM DAX1 siRNA or 5nM scrambled control siRNA (scrambled) and treated for 72h with 10
 7M DHT or left untreated in PRF–
CT. Fifty micrograms of protein lysates were analysed by WB to evaluate the expression of DAX1 and cyclin D1. The expression of GAPDH was
assessed as control of protein loading. Results were obtained after repetitive stripping and reprobing of the same ﬁlters. (B) ChIP assays were carried
out on serum starved MCF-7 cells transfected with 100nM DAX1 siRNA or 100nM scrambled control siRNA (scrambled). Cells were then treated
with 10
 7M DHT for 2h and DNA-associated proteins were precipitated using either anti-DAX1, AR or Pol II antibodies (2mg/sample each). In
control samples (Ig), normal mouse or rabbit IgG were used instead of the primary Abs, as control of Ab speciﬁcity. The region of the cyclin D1
promoter containing the CCND1-ARE site, was detected by PCR using speciﬁc primers listed in the ‘Materials and Methods’ section. Inputs DNA
were ampliﬁed as loading controls. (C) Five-microliters volume of each sample and input from ChIP were used for real-time PCR as reported in the
‘Materials and Methods’ section. Data were statistically analysed by Student’s t-test, *P<0.05 and
«P<0.05 versus scrambled DHT treated.
(D) ChIP assays were carried out as above described. The 50-ﬂanking sequence of the CCND1 containing the Sp1 sites was detected by PCR
using speciﬁc primers listed in the ‘Materials and Methods’ section. Input DNAs were ampliﬁed as loading controls. Results are representative of
three independent experiments.
5362 Nucleic Acids Research, 2010,Vol.38, No. 16The importance of our results is highlighted by recent
studies demonstrating that biologically active DHT
is locally produced in breast carcinoma tissues.
Interestingly, intratumoural DHT levels are positively
associated with AR and 5a-reductase 1 expression but in-
versely correlated with tumour size, Ki-67 and aromatase
expression (78), suggesting that in AR-positive breast car-
cinomas the use of aromatase inhibitors may be more ef-
fective by accumulation of the local DHT concentration.
The biological signiﬁcance of DHT-induced inhibition of
cyclin D1 expression is also pointed out by clinical studies
using tamoxifen as an adjuvant therapy in ER-positive
breast cancers, showing a higher response and better
survival rate in cancers with cyclin D1 low/moderate ex-
pression (7–8). These observations, supported by the wide-
spread expression of AR in primary and metastatic breast
tumours, suggest the possibility that targeting the
AR-signalling pathway could be helpful in improving
new molecular and pharmacological approaches for
breast cancer treatment and to potentiate the eﬀectiveness
of anti-oestrogen adjuvant therapies.
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